Novartis skin cancer drug meets endpoint in trial

Share this article:

Novartis announced today that investigational oral medicine LDE225, for advanced basal cell carcinoma hit, what the drugmaker calls "objective response," or showed a clinically significant tumor response (absence of disease) or a partial response (tumor shrinkage) after six months of treatment in Phase-II trials.

Novartis's head of oncology, Alessandro Riva, stated, "for people living with advanced basal cell carcinoma there are currently limited treatment options," adding, "these results demonstrate the potential for LDE225 to offer a treatment option for this patient population, and we look forward to sharing these data with regulatory authorities worldwide."

Basal cell carcinoma is the most common form of skin cancer, according to the Skin Care Foundation. Novartis has plans to file LDE225 in 2014.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.